{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:14:15Z","timestamp":1790176455094,"version":"4.1.0"},"reference-count":65,"publisher":"Cold Spring Harbor Laboratory","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cold Spring Harb Mol Case Stud"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Chordoma is a rare, orphan cancer arising from embryonal precursors of bone. Surgery and radiotherapy (RT) provide excellent local control, often at the price of significant morbidity because of the structures involved and the need for relatively high doses of RT; however, recurrence remains high. Although our understanding of the genetic changes that occur in chordoma is evolving rapidly, this knowledge has yet to translate into treatments. We performed comprehensive DNA (paired tumor\/normal whole-exome and shallow whole-genome) and RNA (tumor whole-transcriptome) next-generation sequencing analyses of archival sacral and clivus chordoma specimens. Incorporation of transcriptomic data enabled the identification of gene overexpression and expressed DNA alterations, thus providing additional support for potential therapeutic targets. In three patients, we identified alterations that may be amenable to off-label FDA-approved treatments for other tumor types. These alterations include <jats:italic>FGFR1<\/jats:italic> overexpression (ponatinib, pazopanib) and copy-number duplication of <jats:italic>CDK4<\/jats:italic> (palbociclib) and <jats:italic>ERBB3<\/jats:italic> (gefitinib). In a third patient, germline DNA demonstrated predicted pathogenic changes in <jats:italic>CHEK2<\/jats:italic> and <jats:italic>ATM<\/jats:italic>, which may have predisposed the patient to developing chordoma at a young age and may also be associated with potential sensitivity to PARP inhibitors because of homologous recombination repair deficiency. Last, in the fourth patient, a missense mutation in <jats:italic>IGF1R<\/jats:italic> was identified, suggesting potential activity for investigational anti-IGF1R strategies. Our findings demonstrate that chordoma patients present with aberrations in overlapping pathways. These results provide support for targeting the IGF1R\/FGFR\/EGFR and CDK4\/6 pathways as treatment strategies for chordoma patients. This study underscores the value of comprehensive genomic and transcriptomic analysis in the development of rational, individualized treatment plans for chordoma.<\/jats:p>","DOI":"10.1101\/mcs.a003418","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T19:25:13Z","timestamp":1539631513000},"page":"a003418","source":"Crossref","is-referenced-by-count":17,"title":["Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses"],"prefix":"10.1101","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5698-7735","authenticated-orcid":false,"given":"Winnie S.","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Helland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobana","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Cuyugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Byron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"246","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"2021112506164480000_4.6.a003418.1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth0410-248"},{"key":"2021112506164480000_4.6.a003418.2","first-page":"98","article-title":"Durable response of spinal chordoma to combined inhibition of IGF-1R and EGFR","volume":"6","year":"2016","journal-title":"Front Oncol"},{"key":"2021112506164480000_4.6.a003418.3","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1858"},{"key":"2021112506164480000_4.6.a003418.4","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-10-r106"},{"key":"2021112506164480000_4.6.a003418.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42874"},{"key":"2021112506164480000_4.6.a003418.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5449.2528"},{"key":"2021112506164480000_4.6.a003418.7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00428-016-1985-y","article-title":"Whole-transcriptome analysis of chordoma of the skull base","volume":"469","year":"2016","journal-title":"Virchows Arch"},{"key":"2021112506164480000_4.6.a003418.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9543-6"},{"key":"2021112506164480000_4.6.a003418.9","doi-asserted-by":"publisher","DOI":"10.1002\/lary.24420"},{"key":"2021112506164480000_4.6.a003418.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101283"},{"key":"2021112506164480000_4.6.a003418.11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-302"},{"key":"2021112506164480000_4.6.a003418.12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-11-1344"},{"key":"2021112506164480000_4.6.a003418.13","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2514"},{"key":"2021112506164480000_4.6.a003418.14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0290"},{"key":"2021112506164480000_4.6.a003418.15","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s41416-018-0064-3","article-title":"Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma","volume":"118","year":"2018","journal-title":"Br J Cancer"},{"key":"2021112506164480000_4.6.a003418.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5476"},{"key":"2021112506164480000_4.6.a003418.17","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2021112506164480000_4.6.a003418.18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10549-011-1635-7","article-title":"Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer","volume":"132","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2021112506164480000_4.6.a003418.19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu479"},{"key":"2021112506164480000_4.6.a003418.20","doi-asserted-by":"crossref","first-page":"984","DOI":"10.7150\/jca.11371","article-title":"Mutation analysis of nine chordoma specimens by targeted next-generation cancer panel sequencing","volume":"6","year":"2015","journal-title":"J Cancer"},{"key":"2021112506164480000_4.6.a003418.21","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0519"},{"key":"2021112506164480000_4.6.a003418.22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0450"},{"key":"2021112506164480000_4.6.a003418.23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604130"},{"key":"2021112506164480000_4.6.a003418.24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.neo.2017.08.005","article-title":"Targeting the cohesive cluster phenotype in chordoma via \u03b21 integrin increases ionizing radiation efficacy","volume":"19","year":"2017","journal-title":"Neoplasia"},{"key":"2021112506164480000_4.6.a003418.25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00401-016-1574-9","article-title":"Poorly differentiated chordoma with SMARCB1\/INI1 loss: a distinct molecular entity with dismal prognosis","volume":"132","year":"2016","journal-title":"Acta Neuropathol"},{"key":"2021112506164480000_4.6.a003418.26","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.ejca.2015.07.038","article-title":"Imatinib in advanced chordoma: a retrospective case series analysis","volume":"51","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021112506164480000_4.6.a003418.27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000371843","article-title":"Sustained response of a clivus chordoma to erlotinib after imatinib failure","volume":"8","year":"2015","journal-title":"Case Rep Oncol"},{"key":"2021112506164480000_4.6.a003418.28","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu014"},{"key":"2021112506164480000_4.6.a003418.29","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.77"},{"key":"2021112506164480000_4.6.a003418.30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fonc.2018.00208","article-title":"Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer","volume":"8","year":"2018","journal-title":"Front Oncol"},{"key":"2021112506164480000_4.6.a003418.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018846"},{"key":"2021112506164480000_4.6.a003418.32","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"2021112506164480000_4.6.a003418.33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt865"},{"key":"2021112506164480000_4.6.a003418.34","doi-asserted-by":"publisher","DOI":"10.1101\/gr.213348.116"},{"key":"2021112506164480000_4.6.a003418.35","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10306"},{"key":"2021112506164480000_4.6.a003418.36","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"},{"key":"2021112506164480000_4.6.a003418.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2218"},{"key":"2021112506164480000_4.6.a003418.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-010-0767-x"},{"key":"2021112506164480000_4.6.a003418.39","doi-asserted-by":"publisher","DOI":"10.1002\/path.4082"},{"key":"2021112506164480000_4.6.a003418.40","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxh008"},{"key":"2021112506164480000_4.6.a003418.41","doi-asserted-by":"crossref","first-page":"e115909","DOI":"10.1371\/journal.pone.0115909","article-title":"Investigating microenvironmental regulation of human chordoma cell behaviour","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"2021112506164480000_4.6.a003418.42","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2419"},{"key":"2021112506164480000_4.6.a003418.43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605019"},{"key":"2021112506164480000_4.6.a003418.44","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1016\/j.celrep.2018.06.032","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","year":"2018","journal-title":"Cell Rep"},{"key":"2021112506164480000_4.6.a003418.45","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.18632\/oncotarget.13616","article-title":"Genomic and transcriptomic characterization of skull base chordoma","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2021112506164480000_4.6.a003418.46","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts271"},{"key":"2021112506164480000_4.6.a003418.47","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2559.2012.04186.x","article-title":"Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study","volume":"60","year":"2012","journal-title":"Histopathology"},{"key":"2021112506164480000_4.6.a003418.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.02.012"},{"key":"2021112506164480000_4.6.a003418.49","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth0810-575"},{"key":"2021112506164480000_4.6.a003418.50","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22225"},{"key":"2021112506164480000_4.6.a003418.51","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328330c7f0"},{"key":"2021112506164480000_4.6.a003418.52","doi-asserted-by":"crossref","first-page":"e78895","DOI":"10.1371\/journal.pone.0078895","article-title":"Erlotinib inhibits growth of a patient-derived chordoma xenograft","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"2021112506164480000_4.6.a003418.53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28032"},{"key":"2021112506164480000_4.6.a003418.54","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/path.2679","article-title":"Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor\/insulin receptor: potential therapeutic targets in chordoma","volume":"220","year":"2010","journal-title":"J Pathol"},{"key":"2021112506164480000_4.6.a003418.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.3656"},{"key":"2021112506164480000_4.6.a003418.56","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00368"},{"key":"2021112506164480000_4.6.a003418.57","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1471-4159.2012.07917.x","article-title":"Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents","volume":"123","year":"2012","journal-title":"J Neurochem"},{"key":"2021112506164480000_4.6.a003418.58","first-page":"3325","article-title":"Contributions of ATM mutations to familial breast and ovarian cancer","volume":"63","year":"2003","journal-title":"Cancer Res"},{"key":"2021112506164480000_4.6.a003418.59","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2012.016"},{"key":"2021112506164480000_4.6.a003418.60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3270"},{"key":"2021112506164480000_4.6.a003418.61","doi-asserted-by":"publisher","DOI":"10.1002\/path.1969"},{"key":"2021112506164480000_4.6.a003418.62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/gcc.22362","article-title":"Genomic aberrations frequently alter chromatin regulatory genes in chordoma","volume":"55","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"2021112506164480000_4.6.a003418.63","doi-asserted-by":"crossref","first-page":"e0180862","DOI":"10.1371\/journal.pone.0180862","article-title":"PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine\/chemokine receptor interaction pathway","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"2021112506164480000_4.6.a003418.64","doi-asserted-by":"publisher","DOI":"10.1038\/ng.454"},{"key":"2021112506164480000_4.6.a003418.65","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1098"}],"container-title":["Molecular Case Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/mcs.a003418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T14:17:11Z","timestamp":1637849831000},"score":1,"resource":{"primary":{"URL":"http:\/\/molecularcasestudies.cshlp.org\/lookup\/doi\/10.1101\/mcs.a003418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,17]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1101\/mcs.a003418"],"URL":"https:\/\/doi.org\/10.1101\/mcs.a003418","relation":{},"ISSN":["2373-2865","2373-2873"],"issn-type":[{"value":"2373-2865","type":"print"},{"value":"2373-2873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]}}}